Zobrazeno 1 - 2
of 2
pro vyhledávání: '"J P Luijkx"'
Autor:
E C I Woelders, J P Luijkx, L Rodwell, P J C Winkler, A C Dimitriu-Leen, P C Smits, N Van Royen, A W J Van 'T Hof, P Damman, R J M Van Geuns
Publikováno v:
European Heart Journal. 43
Background/Introduction P2Y12 inhibitor monotherapy is a promising novel strategy to reduce bleeding complications compared to DAPT. To determine which patients benefit most, we investigated the effect according to bleeding risk. Purpose The study ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10fb08d59f18002f2776807991510d2b
https://doi.org/10.1093/eurheartj/ehac544.1380
https://doi.org/10.1093/eurheartj/ehac544.1380
Autor:
Nousjka P. A. Vranken, Saman Rasoul, Jasper J. P. Luijkx, Tobias F. S. Pustjens, Sonja Postma, Evelien J. Kolkman, Elvin Kedhi, Sodiqur Rifqi, Michael K. Y. Lee, Henning Ebelt, Béla Merkely, Monica Verdoia, Wojtek Wojakowski, Arnoud A. W. J. van ’t Hof, Harry Suryapranata, Giuseppe De Luca
Publikováno v:
Diabetes/metabolism research and reviews. 38(5)
The optimal duration of dual antiplatelet therapy (DAPT) in patients with diabetes mellitus (DM) admitted with acute coronary syndrome (ACS) and treated with a drug-eluting stent (DES) remains unclear. This is a prespecified sub-study from the Random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4b1f9b17a42b536d3a3be765495343
https://pubmed.ncbi.nlm.nih.gov/35395144
https://pubmed.ncbi.nlm.nih.gov/35395144